Online citations, reference lists, and bibliographies.
← Back to Search

Which Type Of Surgery Should Become The Preferred Procedure For Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy Or Extended Pleurectomy?

M. A. Bedirhan, L. Cansever, A. Demir, Süleyman Ceyhan, H. Akın, Halide Nur Urer, Aysun Olçmen, C. Kocatürk, I. Dinçer
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
PURPOSES Since radiation and chemotherapy have limitations as therapies for malignant pleural mesothelioma (MPM). The type of surgery [extrapleural pneumonectomy (EPP), extended pleurectomy (E/P), and pleurectomy/decortication (P/D)] remains controversial. METHODS This study involves 76 consecutive patients. 58 of the cases were males (76%) with a median age of 53.17±10.93 years. EPP, E/P, and P/D were performed in 31, 20, and 25 cases, respectively. RESULTS The median survival time was 20 months in all patients. Overall, five-year survival rate was 14.3%. The survival rate was significantly better in epithelioid mesothelioma (P=0.049). For EPP cases, the median survival rate was 17 months, and the three-to-five year survival rates were 21% and 17%, respectively. For E/P cases, the median survival rate was 27 months and the three-year and four-year survival rates were 34% and 30%, respectively. For P/D cases, the median survival rate was 15 months and the three-to-five year survival rate was 13% and 0%. There were no statistically significant differences between the three surgical techniques (P=0.088). A comparative analysis indicates only a statistically significant difference in the E/P and P/D comparison (P=0.032). Hospital mortality showed a higher trend in EPP group (EPP: 12.9%, E/P: 0% and P/D: 4%, P=0.145). N2 cases, there were no cases of two-year survival. The survival rate in N2 was comparatively much lower, which was statistically significant (P=0.005). In multivariate analysis, only P/D (OR 0.3, 95% CI: 0.1-0.9, P=0.049) and N2 (OR 1.6, 95% CI: 0.9-2.6, P=0.090) were found to be poor prognostic factors. CONCLUSIONS E/P could be encouraged to EPP with lower mortality rate and better survival trend in MPM. N2 diseases were negative prognostic factors in MPM.
This paper references
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
Neoadjuvant chemotherapy fol lowed by extrapleural pneumonectomy in malignant pleural mesothelioma
W Weder (2004)
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.
R. Flores (2009)
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?
M A Bedirhan (2013)
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
D. Trousse (2009)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
R. Flores (2005)
Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma.
V. Rusch (1997)
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
Long term survival after trimodal therapy in malignant pleural mesothelioma.
R. Fahrner (2012)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
Surgery in mesothelioma--where do we go after MARS?
B. Hiddinga (2013)
Case - control study between extrapleural pneumonectomy and radical pleurectomy / decortication for pathological N 2 malignant pleural mesothelioma
AE Martin-Ucar (2007)
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
WHO classification: pathology & genetics, tumours of the lung, pleura, thymus and heart
W D Travis (2004)
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
R. Federico (2012)
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
T. Yan (2009)
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
[Gene therapy in malignant mesothelioma].
A. O. Tokat (2003)
Future developments in the management of malignant pleural mesothelioma
Paolo Andrea Zucali (2009)
Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?
J. Lindenmann (2013)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
eds. WHO classification: pathology & genetics, tumours of the lung, pleura, thymus and heart
WD Travis (2004)
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
D. Stewart (2004)
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)

This paper is referenced by
Diaphragm and lung–preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10‐year experience
M. Ambrogi (2018)
Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
Y. Ichiki (2020)
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
E. Taioli (2015)
Evaluation of surgical treatment for malignant pleural mesothelioma
Hideyuki Nishi (2015)
[Malignant pleural mesothelioma: new aspects of medical therapy].
S. Kurz (2014)
Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models
B. Nuvoli (2016)
Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?
P. Hountis (2015)
A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma.
I. Opitz (2017)
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.
A. Wolf (2016)
Short‐term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma
M. V. van Gerwen (2018)
A case of surgically treated bilateral metachronous malignant pleural mesothelioma.
M. A. Bedirhan (2019)
Surgery and Multimodality Treatment in Malignant Pleural Mesothelioma
F. Rea (2019)
Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma
G. Marulli (2017)
Semantic Scholar Logo Some data provided by SemanticScholar